Main Menu


A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer

Disease siteBreast cancer

Treatment modality: Combination therapy

Status: In follow-up

Trial details

ALTTO is a Breast International Group (BIG) study with collaborative support provided by the ICR-CTSU. It is a randomised, open label multi-centre phase III study comparing the activity of lapatinib alone versus trastuzumab alone versus trastuzumab followed by lapatinib versus lapatinib concomitantly with trastuzumab in the adjuvant treatment of
patients with ErbB2 overexpressing and/or amplified breast cancer.

Chief Investigator: Professor Ian Smith (UK CI), Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss


Sponsor: GlaxoSmithKline

Funder: GlaxoSmithKline

Further information

Contact details and more information may be found on the ALTTO Trials homepage

ALTTO trials  listing on the UKCRN Portfolio

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.